mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages 181-192

  Kasajima, Atsuko ^a,b   Pavel, Marianne ^a   Darb Esfahani, Silvia ^a   Noske, Aurelia ^c   Stenzinger, Albrecht ^a,e   Sasano, Hironobu ^b   Dietel, Manfred ^a   Denkert, Carsten ^a   Röcken, Christoph ^d   Wiedenmann, Bertram ^a   Weichert, Wilko ^a,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CYTOPLASM; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDGUT; NEUROENDOCRINE TUMOR; PROGNOSIS; PROTEIN EXPRESSION; TUMOR LOCALIZATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL PROLIFERATION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOR SERINE-THREONINE KINASES;

EID: 79251512978     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0126     Document Type: Article

References (40)

1. Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F & Rimm DL 2009 High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clinical Cancer Research 15 4157-4164. (doi:10.1158/1078-0432. CCR-09-0099)
2. Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH & van Hillegersberg R 2008 mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? Journal of Clinical Pathology 61 909-913. (doi:10.1136/jcp.2008.055772)
3. Campbell L, Jasani B, Edwards K, Gumbleton M & Griffiths DF 2008 Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. British Journal of Cancer 98 931-940. (doi:10.1038/sj.bjc.6604243)
4. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J & Ramon y Cajal S 2006 Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107 1801-1811. (doi:10.1002/cncr.22195)
5. Culjkovic B, Topisirovic I & Borden KL 2007 Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6 65-69.
6. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M & Denkert C 2009 Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. Journal of Cancer Research and Clinical Oncology 135 933-941. (doi:10.1007/s00432-008-0529-5)
7. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer 95 1148-1154. (doi:10.1038/sj.bjc.6603419)
8. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B & Pan D 2002 Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nature Cell Biology 4 699-704. (doi:10.1038/ncb847)
9. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M & Grossman AB 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the AKT - mTOR - p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87 168-181. (doi:10.1159/000111501)
10. Hay N & Sonenberg N 2004 Upstream and downstream of mTOR. Genes and Development 18 1926-1945. (doi:10.1101/gad.1212704)
11. Iida S, Miki Y, Ono K, Akahira J, Suzuki T, Ishida K, Watanabe M & Sasano H 2010 Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients. Cancer Science 101 2278-2285. (doi:10.1111/j.1349-7006.2010.01657.x)
12. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA & Nagle RB 2006 Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66 1203-1212. (doi:10.1002/pros.20410)
13. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT - mTOR pathway. Journal of Clinical Oncology 28 245-255. (doi:10.1200/JCO.2008.21.5988)
14. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 934-959. (doi:10.1002/cncr.11105)
15. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
16. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC & Meric-Bernstam F 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocrine-Related Cancer 15 257-266. (doi:10.1677/ERC-07-0202)
17. Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Röske A, Sehouli J, Dietel M & Denkert C 2008 Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncology Reports 20 1409-1417. (doi:10.3892/or-00000160)
18. Oberg K & Jelic S 2008 ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 19 104-105.
19. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M et al. 2006 Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clinical Cancer Research 12 3935-3941. (doi:10.1158/1078-0432.CCR-05-2202)
20. Plöckinger U & Wiedenmann B 2007 Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Archive 451 71-80. (doi:10.1007/s00428-007-0446-z)
21. Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G & Papotti M 2010 Mammalian target of rapamycin (mTOR) signaling activation patterns in neuroendocrine tumors of the lung. Endocrine-Related Cancer 17 977-987. (doi:10.1677/ERC-10-0157)
22. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archive 449 395-401. (doi:10.1007/s00428-006-0250-1)
23. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archive 451 757-762. (doi:10.1007/s00428-007-0452-1)
24. Rini BI 2008 Temsirolimus, an inhibitor of mammalian target of rapamycin. Clinical Cancer Research 14 1286-1290. (doi:10.1158/1078-0432.CCR-07-4719)
25. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J & Ramon y Cajal S 2007 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clinical Cancer Research 13 81-89. (doi:10.1158/1078-0432.CCR-06-1560)
26. Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA et al. 2008 Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 14 1318-1327. (doi:10.1261/rna.950608)
27. Sabatini DM 2006 mTOR and cancer: insights into a complex relationship. Nature Reviews. Cancer 6 729-734. (doi:10.1038/nrc1974)
28. Sahin F, Kannangai R, Adegbola O, Wang J, Su G & Torbenson M 2004 mTOR and P70 S6 kinase expression in primary liver neoplasms. Clinical Cancer Research 10 8421-8425. (doi:10.1158/1078-0432.CCR-04-0941)
29. Sánchez-Fructuoso AI 2008 Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opinion on Drug Metabolism & Toxicology 4 807-819. (doi:10.1517/17425255.4.6.807)
30. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor - mTOR complex. Science 307 1098-1101. (doi:10.1126/science.1106148)
31. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M et al. 2010 Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemotherapy and Pharmacology 65 889-893. (doi:10.1007/s00280- 009-1094-6)
32. Sobin LH, Gospodarowicz MK & Wittekind C 2009 TNM Classification of Malignant Tumours, 7th edn, pp 86-95. Holboken, NJ: John Wiley & Sons.
33. Tampellini M, Longo M, Cappia S, Bacillo E, Alabiso I, Volante M, Dogliotti L & Papotti M 2007 Co-expression of EGF receptor, TGFα and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Archive 450 321-328. (doi:10.1007/s00428-007- 0370-2)
34. Toumpanakis CG & Caplin ME 2008 Molecular genetics of gastroenteropancreatic neuroendocrine tumors. American Journal of Gastroenterology 103 729-732. (doi:10.1111/j.1572-0241.2007.01777.x)
35. Whalen SG, Gingras AC, Amankwa L, Mader S, Branton PE, Aebersold R & Sonenberg N 1996 Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins. Journal of Biological Chemistry 271 11831-11837. (doi:10.1074/jbc.271.20.11831)
36. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008a One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
37. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A et al. 2008b Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology 26 4311-4318. (doi:10.1200/JCO.2008.16.7858)
38. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
39. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D & Yu D 2004 Activation of the Akt/mammalian target of rapamycin/ 4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research 10 6779-6788. (doi:10.1158/1078-0432.CCR-04- 0112)
40. Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH & Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 54-60. (doi:10.1159/000100057)